Lymphoma Clinical Trials in New York

Showing 281-300 of 620 trials

Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma

NCT04231734

This study evaluates adherence to a ketogenic diet in patients with low tumor burden, treatment-naïve mantle cell lymphoma.

Mantle Cell LymphomaKetogenic Dieting

Weill Medical College of Cornell UniversityStarted Apr 2023

New York, New York, United States

COMPLETEDPhase 2< 1 mile

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

NCT03542266

This is a phase II, multi-center study to determine the efficacy and safety of first-line CC-486 plus CHOP in patients with PTCL who have received no prior systemic therapy. The study has a sample size of 20, and follows two-stage minimax design for primary efficacy analysis.

Previously Untreated Peripheral T-cell Lymphoma

Weill Medical College of Cornell University21 participantsStarted Jun 2018

Tampa, Florida, United States • St Louis, Missouri, United States • New York, New York, United States +1 more locations

COMPLETEDPhase 1/2< 1 mile

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

NCT03192202

The investigators plan to investigate AFM13 and evaluate its ability to facilitate and redirect the Natural Killer (NK) cells in eliminating CD30-positive lymphoma targets in the skin and, by inference, other organs involved by the lymphoma.

Lymphoma, T-Cell, Cutaneous

Ahmed Sawas18 participantsStarted Jul 2017

New York, New York, United States

Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Lymphoma Trials in Other Cities

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

PET Imaging of Subjects Using 124I-PU-AD

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Safety Study of SEA-CD40 in Cancer Patients

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

Dose Optimization Study of Idelalisib in Follicular Lymphoma

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Other Conditions in New York